NCT02949284View on ClinicalTrials.gov

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

November 20, 2025

Study Completion Date

November 20, 2026

Conditions
Stage II Prostate AdenocarcinomaStage III Prostate Adenocarcinoma
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Androgen Receptor Antagonist ARN-509

Given PO

BIOLOGICAL

Gonadotropin-releasing Hormone Analog

Given SC

DRUG

Prednisone

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Radical Prostatectomy

Undergo radical prostatectomy

Trial Locations (2)

06519

Yale Cancer Center, New Haven

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER